- A Look to the Future of Cancer Diagnostics
compiles insight from four veterinary cancer experts
- Report provides insight into the clinical impact of early
cancer detection, and recent advances
- Experts also reviewed data on the Nu.Q™ Vet Cancer Screening
Test, providing opinion and guidance ahead of expected launch
- Download a copy of the report here
AUSTIN, Nov. 10, 2020 /PRNewswire/ -- VolitionRx Limited
(NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics
company developing simple, easy to use, cost effective blood tests
to help diagnose a range of cancers and other diseases in both
humans and animals, has published a report with contributions from
four global leaders in veterinary oncology, ahead of the expected
launch of its first product, the Nu.Q™ Vet Cancer Screening Test.
The comprehensive new report for veterinarians, titled A
Look to the Future of Cancer Diagnostics, explores the
promise of molecular diagnostics in veterinary oncology, especially
for hard to find tumors, and introduces Volition's Nu.Q™ technology
and Nu.Q™ Vet Cancer Screening Test.
The report is the outcome of a round table event, hosted by
Volition Veterinary Diagnostics Development, LLC, with an expert
panel including: Dr. Tim Fan Ph.D., DVM, DACVIM, Program
Leader, Cancer Discovery Platforms and Professor, Veterinary
Clinical Medicine, at the Cancer Center at Illinois; Dr. David Vail DVM, DACVIM,
Professor and Barbara A. Suran Chair in Comparative Oncology, and
Director of the Barbara A. Suran Comparative Oncology Research
Center; and Dr. Sue Ettinger DVM, DACVIM, a practicing veterinary
cancer specialist, international speaker and author. Dr. Heather
Wilson-Robles DVM, DACVIM, Professor of Oncology at Texas A&M University and Chief Medical Officer
at Volition Veterinary was also a panelist.
The panel reviewed data from results presented at the Veterinary
Cancer Society Virtual Annual Conference in October, which demonstrated the successful use of the
blood-based Nu.Q™ Vet Cancer Screening Test for dogs with lymphoma
and hemangiosarcoma, a cancer of blood vessel walls, which together
make up approximately one-third of canine cancers. They also
discussed topics including the potential of early cancer diagnosis
to help improve the treatment and quality of life, as well as
supporting the clinical decision-making process.
"I was very pleased to participate in the round table and the
subsequent report," Dr. Tim Fan
commented. "Volition's platform is very exciting. Nucleosomes are
very stable biomarkers that can be found in circulation and
bringing this technology to the veterinary market is a very
important first step. I look forward to seeing Volition adapt to
the needs of the clients, pets and pet-owners that will benefit
from this diagnostic test."
Dr. Heather Wilson-Robles said:
"Dr. Fan, Dr. Vail and Dr. Ettinger are leading the field in
veterinary oncology. I am hugely grateful for their insight, expert
opinion and guidance at this key moment as we prepare for the
launch of our first product and take on the challenge of earlier
detection of canine cancers. Cancer screening is not as commonplace
in animal health as it is in human health, but blood tests like the
Nu.Q™ Vet Cancer Screening Test could transform how we manage
cancer in companion animals."
To learn more about Volition Veterinary, Nu.Q™ Vet please visit
our new webpage at https://volition.com/veterinary or
download a copy of the report, A Look to the Future of Cancer
Diagnostics here.
About the Nu.Q™ Vet Cancer Screening Test
Cancer is the most common cause of death in dogs over the age of
two years old in the U.S. and up to 50% of all dogs over the age of
10 develop cancer in their lifetime. Together, Lymphoma and
Hemangiosarcoma make up approximately one third of canine cancers.
Currently, dogs suspected of having cancer are required to undergo
a variety of diagnostic tests that may be expensive, time consuming
and/or painful for the animal. The Nu.Q™ Vet Cancer Screening Test
is a low-cost, easy to use ELISA-based screening test that measures
and identifies circulating nucleosomes, which are early markers of
cancer, from a simple blood sample to enable a streamlined and less
invasive diagnostic process.
About Volition
Volition is a multi-national epigenetics company developing
simple, easy to use, cost effective blood tests to help diagnose a
range of cancers and other diseases. Early diagnosis has the
potential to not only prolong the life of patients, but also to
improve their quality of life. The tests are based on the science
of Nucleosomics™, which is the practice of identifying and
measuring nucleosomes in the bloodstream or other bodily fluid - an
indication that disease is present. Volition is primarily focused
on human diagnostics but also has a subsidiary focused on animal
diagnostics.
Volition's research and development activities are centered in
Belgium, with additional offices
in Texas, London and Singapore, as the company focuses on bringing
its diagnostic products to market.
Nucleosomics™ and Nu.Q™ and their respective logos are
trademarks of Volition and its subsidiaries.
For more information about Volition, visit Volition's website
(www.volition.com) or connect
with us via:
Twitter: https://twitter.com/volitionrx
LinkedIn: https://www.linkedin.com/company/volitionrx
Facebook: https://www.facebook.com/VolitionRx/
YouTube: https://www.youtube.com/user/VolitionRx
The contents found at Volition's website address, Twitter,
LinkedIn, Facebook, and YouTube are not incorporated by reference
into this document and should not be considered part of this
document. The addresses for Volition's website, Twitter,
LinkedIn, Facebook, and YouTube are included in this document as
inactive textual references only.
Media / Investor Contacts
Louise Batchelor,
Volition
mediarelations@volition.com
+44 (0)7557
774620
|
Scott Powell,
Volition
investorrelations@volition.com
+1 (646) 650
1351
|
Jen Lewis,
Pegasus
jen.lewis@thisispegasus.co.uk
+44 (0)7809
867943
|
Joseph Green,
Edison Advisors
jgreen@edisongroup.com
+1 (646) 653
7030
|
Safe Harbor Statement
Statements in this press release may be "forward-looking
statements" within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended, that concern matters that involve risks and
uncertainties that could cause actual results to differ materially
from those anticipated or projected in the forward-looking
statements. Words such as "expects," "anticipates," "intends,"
"plans," "aims," "targets," "believes," "seeks," "estimates,"
"optimizing," "potential," "goal," "suggests," "could," "would,"
"should," "may," "will" and similar expressions identify
forward-looking statements. These forward-looking statements relate
to the timing of the commercial launch of Volition's test platforms
for early detection of cancer and other diseases. Volition's actual
results may differ materially from those indicated in these
forward-looking statements due to numerous risks and uncertainties,
including, without limitation, results of studies testing the
efficacy of its tests. For instance, if Volition fails to develop
and commercialize diagnostic or prognostic products, it may be
unable to execute its plan of operations. Other risks and
uncertainties include Volition's failure to obtain necessary
regulatory clearances or approvals to distribute and market future
products; a failure by the marketplace to accept the products in
Volition's development pipeline or any other diagnostic or
prognostic products Volition might develop; Volition's failure to
secure adequate intellectual property protection; Volition will
face fierce competition and Volition's intended products may become
obsolete due to the highly competitive nature of the diagnostics
market and its rapid technological change; downturns in domestic
and foreign economies; and other risks identified in Volition's
most recent Annual Report on Form 10-K and Quarterly Reports on
Form 10-Q, as well as other documents that Volition files with the
Securities and Exchange Commission. These statements are based on
current expectations, estimates and projections about Volition's
business based, in part, on assumptions made by management. These
statements are not guarantees of future performance and involve
risks, uncertainties and assumptions that are difficult to predict.
Forward-looking statements are made as of the date of this release,
and, except as required by law, Volition does not undertake an
obligation to update its forward-looking statements to reflect
future events or circumstances.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/volition-veterinary-presents-expert-report-ahead-of-first-product-launch-301169621.html
SOURCE VolitionRx Ltd